Ranjan Dutta1, Bruce D Trapp. 1. Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline. This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis. RECENT FINDINGS: The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases. Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions. SUMMARY: Available therapies for multiple sclerosis patients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosis patients. Development of therapies to benefit progressive multiple sclerosis patients will require a better understanding of the pathogenesis of progressive multiple sclerosis. This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosis patients.
PURPOSE OF REVIEW: The predominant clinical disease course of multiple sclerosis starts with reversible episodes of neurological disability, which transforms into progressive neurological decline. This review provides insight into the pathological differences during relapsing and progressive phases of multiple sclerosis. RECENT FINDINGS: The clinical course of multiple sclerosis is variable, and the disease can be classified into relapsing and progressive phases. Pathological studies have been successful in distinguishing between these two forms of the disease and correlate with the clinical findings in terms of cellular responses, the inflammatory environment, and the location of lesions. SUMMARY: Available therapies for multiple sclerosispatients, while effective during the relapsing phase, have little benefit for progressive multiple sclerosispatients. Development of therapies to benefit progressive multiple sclerosispatients will require a better understanding of the pathogenesis of progressive multiple sclerosis. This review discusses and compares the pathological findings in relapsing and progressive multiple sclerosispatients.
Authors: Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp Journal: Ann Neurol Date: 2012-10-17 Impact factor: 10.422
Authors: René Große-Veldmann; Birte Becker; Sandra Amor; Paul van der Valk; Cordian Beyer; Markus Kipp Journal: Mol Neurobiol Date: 2015-09-12 Impact factor: 5.590